FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1290-1291 April 27, 2000 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Palella, F. J. Related Article by Staszewski, S. PubMed Citation

To the Editor: Staszewski et al. (Dec. 16 issue)¹ report that "the combination of efavirenz, zidovudine, and lamivudine has greater antiviral activity . . . than the combination of indinavir, zidovudine, and lamivudine." However, their conclusions may have been overstated. Open-label studies such as theirs are less expensive, are easier to perform, and require fewer pills than randomized studies, but the design may not be adequate to compare two very different treatments, in terms of both the number of pills and the dosage (four pills of indinavir taken three times daily without food and three pills of efavirenz taken once . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.